Compared with free siRNA, HSA-coated lipid nanoparticles loaded with siRNA demonstrated significant gene knockdown in various breast cancer cell lines, including aggressive TNBC variants, and achieved tumor-specific gene silencing in xenograft models with superior pharmacokinetics. This evidence concerns the gene ALB and neoplasm.